HomeCompareEXN vs PFE

EXN vs PFE: Dividend Comparison 2026

EXN yields 677.97% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EXN wins by $698060.91M in total portfolio value
10 years
EXN
EXN
● Live price
677.97%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$698060.95M
Annual income
$541,067,584,452.82
Full EXN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — EXN vs PFE

📍 EXN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEXNPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EXN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EXN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EXN
Annual income on $10K today (after 15% tax)
$57,627.12/yr
After 10yr DRIP, annual income (after tax)
$459,907,446,784.90/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, EXN beats the other by $459,907,424,464.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EXN + PFE for your $10,000?

EXN: 50%PFE: 50%
100% PFE50/50100% EXN
Portfolio after 10yr
$349030.50M
Annual income
$270,533,805,355.77/yr
Blended yield
77.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EXN
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EXN buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEXNPFE
Forward yield677.97%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$698060.95M$49.6K
Annual income after 10y$541,067,584,452.82$26,258.71
Total dividends collected$685272.60M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EXN vs PFE ($10,000, DRIP)

YearEXN PortfolioEXN Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$78,497$67,796.61$9,153$693.39+$69.3KEXN
2$581,356$497,364.87$8,593$849.25+$572.8KEXN
3$4,064,621$3,442,569.86$8,336$1,066.78+$4.06MEXN
4$26,843,663$22,494,518.82$8,437$1,384.80+$26.84MEXN
5$167,562,735$138,840,015.15$9,013$1,875.40+$167.55MEXN
6$989,257,646$809,965,519.98$10,306$2,680.72+$989.25MEXN
7$5,527,550,699$4,469,045,016.92$12,820$4,101.38+$5527.54MEXN
8$29,251,975,998$23,337,496,750.85$17,673$6,826.70+$29251.96MEXN
9$146,722,776,064$115,423,161,745.79$27,543$12,591.86+$146722.75MEXN
10$698,060,954,841$541,067,584,452.82$49,560$26,258.71+$698060.91MEXN

EXN vs PFE: Complete Analysis 2026

EXNStock

Excellon Resources Inc., a silver mining and exploration company, acquires, explores, develops, and exploits mineral properties in Mexico and Canada. The company primarily explores for silver, lead, zinc, and gold deposits. It holds 100% interests in the Platosa property covering an area of approximately 11,000 hectares located in Durango State, Mexico; the Evolución property that covers an area of 45,000 hectares situated in the states of Durango and Zacatecas, Mexico; and the Silver City Project totaling an area of 164 square kilometers in Saxony, Germany. It also holds 100% interests in the Kilgore Project that covers an area of 6,788 located in Clark County, Southeastern Idaho; and the Oakley Project covering an area of 2,833 hectares in Oakley, Idaho. The company was incorporated in 1987 and is based in Toronto, Canada.

Full EXN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EXN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EXN vs SCHDEXN vs JEPIEXN vs OEXN vs KOEXN vs MAINEXN vs JNJEXN vs MRKEXN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.